Recycled glass as a partial replacement for fine aggregate in structural concrete – Effects on compressive strength

Waste management is becoming a major issue for communities worldwide. Glass, being nonbiodegradable, is not suitable for addition to landfill, and as such recycling opportunities need to be investigated. Due to the high material consumption of the construction industry, the utilisation of waste glass as a partial replacement for fine aggregate in structural concrete is particularly attractive. This project aimed to determine the level of glass replacement resulting in optimal compressive strength. Three concrete samples were tested at 7 and 28 days, for glass replacement proportions of 15, 20, 25, 30 and 40%. Compressive strength was found to increase up to a level of 30%, at which point the strength developed was 9% and 6% higher than the control after 7 and 28 days respectively. This demonstrates that concrete containing up to 30% fine glass aggregate exhibits higher compressive strength development than traditional concret

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

Metronomic chemotherapy describes the close, regular administration of chemotherapy drugs at less-toxic doses over prolonged periods of time. In 2015, the results of randomized phase III clinical trials demonstrated encouraging, albeit limited, efficacy benefits of metronomic chemotherapy regimens administered as adjuvant maintenance therapy for the treatment of breast cancer, or as maintenance therapy in combination with an antiangiogenic agent for metastatic colorectal cancer. Owing to the investigational nature of this approach, metronomic chemotherapy regimens are highly empirical in terms of the optimal dose and schedule for the drugs administered; therefore, greater knowledge of the pharmacokinetics of metronomic chemotherapy is critical to the future success of this treatment strategy. Unfortunately, such preclinical and clinical pharmacokinetic studies are rare. Herein, we present situations in which active drug concentrations have been achieved with metronomic schedules, and discuss their associated pharmacokinetic parameters. We summarize examples from the limited number of clinical studies in order to illustrate the importance of assessing such pharmacokinetic parameters, and discuss the influence this information can have on improving efficacy and reducing toxicity